Dizal Reports the P-III (WU-KONG28) Trial Results on Zegfrovy (Sunvozertinib) in EGFRm NSCLC

Why It Matters

The trial establishes the first oral targeted therapy to outperform chemotherapy in this hard‑to‑treat EGFR exon 20 NSCLC subgroup, positioning Zegfrovy to reshape first‑line standards and expand treatment options worldwide.

Key Takeaways

• Zegfrovy achieved statistically significant PFS improvement over chemotherapy
• Trial showed higher ORR, longer DOR, and greater DCR
• Data span Asia, EU, North and South America
• Company will seek NDA based on Phase 3 results
• Potential new first‑line standard for EGFR exon20 NSCLC

Pulse Analysis

The EGFR exon 20 insertion mutation represents a niche yet aggressive subset of non‑small cell lung cancer, historically resistant to first‑generation EGFR inhibitors and reliant on cytotoxic chemotherapy. Zegfrovy (sunvozertinib), a selective oral tyrosine‑kinase inhibitor, was engineered to fit the unique structural conformation of exon 20 insertions, offering a biologically rational alternative that can be administered once daily. This mechanistic advantage sets the stage for a paradigm shift in how oncologists approach this patient cohort, especially as the global market seeks more tolerable, targeted options.

In the WU‑KONG28 Phase 3 trial, over 600 patients across Asia, Europe, North America, and South America received either Zegfrovy monotherapy or a platinum‑based doublet chemotherapy regimen. The primary endpoint—progression‑free survival assessed by blinded independent central review—was met with a hazard ratio indicating a clear survival benefit. Secondary metrics reinforced the advantage: confirmed overall response rate, duration of response, and disease control rate all exceeded those of chemotherapy, underscoring both efficacy and durability. These results not only satisfy regulatory thresholds but also provide clinicians with robust data to justify a switch from traditional chemo to a targeted oral regimen.

Dizal’s intent to file a new drug application leverages the trial’s positive outcomes and the company’s recent FDA accelerated approval for Zegfrovy in later‑line settings. A successful NDA could secure first‑line labeling, unlocking substantial market potential in a segment projected to grow as genomic testing becomes routine. Moreover, the data may prompt payers and guideline committees to reevaluate treatment algorithms, accelerating adoption of precision oncology for EGFR exon 20 NSCLC patients worldwide.